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Recently, bisphosphonates (BPs) have been widely used in medical practice as anti-resorptive agents owing to their
anti-osteoclatic action. In addition, these compounds are also used for their analgesic action and their potential
anti-tumour effect. Patients treated with BPs may subsequently develop osteonecrosis of the jaw or maxillary bone
after minor local trauma including dental work, recently labelled as bisphosphonate osteonecrosis of jaw (BRONJ).
However, the etiopathogenic mechanisms of this pathological condition are poorly understood. Although, several
pathways have been proposed for BRONJ occurrence, no single model can explain all morphological changes
observed at the macro- and microscopic level. Recent research suggests that BPs may promote an anti-angiogenic
effect which contributes directly to the clinical features associated with BRONJ. Remarkably, the anti-angiogenic
effect promoting BRONJ might be in keeping with the anti-neoplastic action of BPs. The current review, presents
clinical diagnostic criteria. In addition, based on our own experience we describe the histopathological criteria for
diagnosis of BRONJ and the possible pathways which may lead to this frustrating pathological condition.Introduction
Bisphosphonates (BPs) are a group of pharmacological
agents used as anti-osteoclastic, anti- resorptive agents
in calcium metabolism disorders such as osteoporosis,
multiple myeloma, Paget’s disease and hypercalcemia of
malignancy [1]. The primary objectives of administering
these drugs are to improve bone morphology, prevent
bone destruction and pathologic fractures, and reduce
pain associated with the metastatic bone disease whilst
decelerating bone resorption [2-4]. Interestingly, BPs re-
sist hydrolysis in the gut and possess an anti-resorptive
action inhibiting hydroxyapatite dissolution [5,6]. Licata
et al. (2005) and Michaelson et al. (2005) have noted
that the most important effect of these pharmacological* Correspondence: e_petcu@hotmail.com
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reproduction in any medium, provided the oragents is represented by promoting apoptosis in osteo-
clasts [7,8].
Chemically, BPs represent pyrophosphate analogs pos-
sessing two variable regions, R1 and R2 on the carbon
atom of BPs molecule attached to basic P-C-P structure.
This allows variations in molecular structure and a range
of potency corresponding to the changes in the structure
[9]. The group occupying R1 position, usually hydroxyl,
enhances the molecule’s affinity to bone (calcium crystals)
and the variable group at R2 position decides its anti-
resorptive action, specifically its potency and efficacy [9].
Classically, BPs have been classified into: non-nitrogen
containing BPs (NNBP) and nitrogen containing BPs
(NBP) depending on the presence or absence of nitro-
gen in their R2 group. However, Russell et al. [10] fur-
ther divided the NBPs into Alkyl-amino and Heterocyclic
NBPs based on the mode of action (Table 1).
Clinically, both the NNBPs and NBPs are used as anti-
resorptive agents (Table 2) but the NNBP are known to
be less potent and thus are mainly used in managementl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Bisphosphonates: types and mode of action
Generation Type Examples Mode of action
First NNBPs Etidronate Formation of an ATP derivative that impairs osteoclast function
and induces osteoclastic apoptosis
Clodronate
Tiludronate
Second Alkyl-amino NBPs Pamidronate Inhibits sterol synthesis via the mevalonate pathway specifically
inhibiting its Farnesyl pyrophosphate synthase (FPPS) enzyme
Alendronate
Ibandronate
Olpadronate
Third Heterocyclic NBPs Risedronate Inhibits FPPS enzyme and stabilize conformational changes
Zoledronate
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most potent BPs used in severe bone resorption cases
like in malignancies (Table 2).
BPs: side-effects
Orally administered BPs may induce recurrent ulcers with
burning sensation and blisters in the oral cavity, erosive
oesophagitis, oesophagal stenosis, uveitis, gastric ulcera-
tions and abdominal pain [11-13]. However, more serious
effects such as bisphosphonate-related osteonecrosis of
jaw (BRONJ), is seen most commonly after intravenous
NBPs such as pamidronate and zoledronate [14].
BRONJ: epidemiological trends
The first clinical description of BRONJ by Marx et al.
(2003) ushered several reports from all across the world
where BPs are used [15]. In general, intravenous nitro-
gen containing BPs shows higher incidence of BRONJ
but a large variation ranging from 0.0% to 28% has been
reported [16-18] depending upon the specific type of
BPs used, single or multiple BPs used concomitantly or
sequentially, duration of therapy and the condition for
which BPs were administered. In addition oral BPs haveTable 2 Bisphosphonates: potency, administration and main
Type of BPs Potency Administration
NNBPs
Etidronate 1 Oral
Clodronate 10 Oral/ Intravenous
Tiludronate 10 Oral
NBPs
Pamidronate 100 Intravenous
Alendonate 500 Oral
Ibandronate 1000 Oral, Intravenous
Risedronate 2000 Oral, Intravenous
Zoledronate 10000 Intravenousalso been associated with BRONJ, although at much
lower percentage, not more that 4% [19,20].
BRONJ: clinical diagnostic criteria
In 2007, the American Association of Oral and Maxillo-
facial Surgeons and the American Society for Bone and
Mineral Research described BRONJ as an area of ex-
posed bone in the maxillofacial region in a patient on
BPs or who has taken in the past these pharmacological
agents, without any history of radiotherapy. Further-
more, the lesions must not be healed within 8 weeks
after identification by a healthcare practitioner to qualify
as a BRONJ case [21,22]. Recently, it was reported a cli-
nical variant of BRONJ that lacked bone exposure, albeit
fulfilling all other essential criteria for BRONJ [23,24].
This warrants the addition of various other clinical signs
and symptoms into the diagnostic criteria (Table 3).
A careful application of these criteria is of paramount
importance as other intraoral conditions such as gingi-
vitis and periodontal disease, mucositis, periapical le-
sions due to pulpal infection and resulting osteomyelitis,
sinusitis, bone tumours (primary and metastasic) and os-
teoradionecrosis need to be ruled out.indications
Main Indications
Osteoporosis, Paget’s disease of bone
Osteoporosis, Paget’s disease of bone
Paget’s disease of bone
Osteolytic bone metastases of breast cancer and osteolytic
lesions of multiple myeloma, Paget’s disease of bone
Osteoporosis, Paget's disease of bone
Osteoporosis
Osteoporosis, Paget’s disease of bone, osteolytic lesions of multiple
myeloma, hypercalcemia of malignancy
Osteolytic lesions of multiple myeloma and metastases from
solid tumors, hypercalcemia of malignancy
Table 3 BRONJ: clinical signs and symptoms
Classical sign of BRONJ Possible clinical signs and symptoms
associated but not limited to BRONJ
Exposed necrotic jaw bone Pain in tooth or bone
Suppuration
Swelling
Sinus and fistula related to jaw bone
Mobility of teeth
Trismus
Non-healing extraction sockets
Soft tissue ulcerations
Gross mandibular deformity
Sequestration of bone
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As other types of osteonecrosis determined by different
etiologies, BRONJ is characterized by the presence of os-
teocyte-depleted bone lacunae. Our diagnostic experience
suggests that this avascular necrosis is characterized by la-
cunae osteocyte depletion which is more obvious in the
deeper layers of the bone while the lacunae located to-
wards the surface of the bone lamellae will lose the osteo-
cytes at a later stage (Figure 1).
The associated morphological features of this specific
type of avascular necrosis are quite heterogeneous. Some
areas of the affected bone with show extensive hae-
morrhage associated with massive chronic inflammatory
cells infiltrate represented by lymphocytes and plasma
cells which is best observed towards the surface of the
bone (Figures 2, 3). In addition, a significant number ofosteoclast
osteoblasts
Figure 1 BRONJ: Empty lacunae are seen in the centre of the bone wthese cells are osteoclasts which continue to exert their
characteristic bone resorptive action in parallel with the
on-going lacunar depletion of osteocytes (Figure 4).
BRONJ: the anti-angiogenic side effect of BPs treatment
It is known that angiogenesis or formation of new im-
mature blood capillaries is an essential factor in healing
of wounds as well as invasion of normal tissues by ma-
lignant cells [25]. Also, normal vascularization represents
an essential requirement for tissue homeostasis, local im-
munity and adequate regeneration or repair of all vital tis-
sues of the body, more so in case of bone due to its high
turnover rate. In a recent study by Wehrhan et al. (2011),
mucoperiosteal tissue samples from BRONJ cases and
controls were assessed for vascularization with CD31 stai-
ning and neo-angiogenesis by CD105 evaluation. It was
reported that although there was no difference in vascu-
larization between sample groups, there were significantly
fewer CD105-positive vessels in BRONJ samples sug-
gesting that neo-angiogenesis was suppressed in BRONJ
cases [26].
Vascular endothelial growth factor (VEGF), in circula-
tion as well as local VEGF mRNA expression, is consid-
ered a classic parameter of angiogenesis. Remarkably, in
non-small cell lung cancer cell lines, zoledronic acid
promotes a significant reduction in mRNA and protein
expression of VEGF [27]. Moreover, serum VEGF levels
and other cytokines involved in angiogenesis such as
interleukin-17, have also been found to decrease after
administration of zoledronate or pamidronate [28-30]. It
is very important to note that BPs determine an efficient
decrease of VEGF at 24 hours after administration. The
VEGF drop is sustained and it has been noted at 7 daysosteocytes in 
lacunae
empty lacunae
necrosis
hile towards the surface some lacunae display their osteocytes.
haemorrhage
osteoclasts
chronic  inflammatory 
cells
Figure 2 BRONJ: Haemorrhage and chronic inflammatory cells infiltrate.
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nate administration [28-30].
Although, there are no studies evaluating the duration
of anti-VEGF effect after BPs treatment, it might be
possible to be time limited. In vitro and in vivo experi-
ments have revealed that clodronate is an efficient anti-
angiogenic agent. The clodronate-related anti-angiogenesis
seems to be related to its direct inhibitory action on endo-
thelial cell proliferative activity coupled with inhibition of
powerful pro-angiogenic factors such as fibroblast-growth
factor 2 (FGF2) [31].
Other authors have reported that NBPs have a signi-
ficant anti-angiogenic effect inhibiting human umbilicalne
Figure 3 BRONJ: Chronic inflammatory cells infiltrate.vein endothelial cells (HUVEC) proliferation, adhesion,
survival, migration and actin stress fiber formation by
interfering with protein prenylation [32,33]. More impo-
rtantly, these studies have revealed that NBPs such as
zoledronic acid inhibit endothelial cells function and sur-
vival by acting on ERK1/2, JNK, Rock, FAK and PKB in a
prenylation dependent reaction [32]. Recent studies per-
formed on human breast cancer cell lines suggest that pa-
midronate and clodronate have a robust anti-angiogenic
action on the HIF-1alpha/VEGF axis via inhibition of the
PI-3K/AKT/mTOR signaling pathways. In addition, both
agents inhibit the pro-angiogenic action of IGF-1 on
breast cancer cells lines [34]. It is noteworthy to mentionchronic inflammatory cells
crosis
osteoclasts
lymphocytecell
plasma cell
Figure 4 BRONJ: Osteoclasts, lymphocytes and plasma cells.
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their inhibition of the endothelial progenitor cell differen-
tiation. Studies conducted in vitro have shown that at low
doses, zoledronic acid inhibits the differentiation of endo-
thelial progenitor cells while at high doses it will induce
apoptosis of endothelial progenitor cells which seems to
be achieved via inhibition of prenylation of small G pro-
teins [35] (Figure 5).
Our own histological evaluation of patients treated with
BPs has confirmed that BRONJ represents an avascular
process of necrosis of the jaw bone due to the lack of
blood vessels in the necrotic areas paradoxically associatedFigure 5 Bisphosphonates: mechanisms of anti-angiogenesis.with an on-going bone resorptive action induced by osteo-
clasts. However, numerous studies have revealed that bis-
phosphonates inhibit the osteoclasts by preventing their
differentiation from their marrow precursors or inhibiting
the mevalonate pathway which is crucial for their func-
tionality [36,37]. Therefore, the presence of multinuclea-
ted giant cells osteoclasts in BRONJ patients is puzzling.
As mentioned before, we have been able to observe rou-
tinely osteoclasts in histological slides prepared with tissue
removed from the lesional and peri-lesional BRONJ area.
This suggests that the anti- osteoclastic action of BPs
could be limited and once they re-appear in the bone,
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that the anti-osteoclastic and the anti- angiogenic action
of BPs are not achieved through the same pathway but
their final effect is summative in producing BRONJ.
Closely related to their anti-angiogenic effect, the BPs
may affect the soft tissue structures seen in the imme-
diate vicinity of the jaw or maxillary bone, potentially
creating a vicious circle whereby the anti-angiogenesis is
enhanced and complicated by soft tissue cells damage.
In studies with oral keratinocyte/model, BPs were shown
to induce senescence, apoptosis and inhibition of cell
growth by blocking FPPS enzyme of cholesterol biosyn-
thetic pathway [38-43] which probably indirectly interfere
with the blood supply of the bone. This is the same mo-
lecular mechanism through which NBPs inhibit osteoclast
function, promoting apoptosis and preventing invasion of
tumor cells (Figure 6).
A histological evaluation of BRONJ has revealed a re-
duced p53 gene expression of tissue samples via meva-
lonate pathway which results in a reduced numbers of
basal epithelial progenitor cells which could result in an
impaired healing capacity of oral mucosa [44]. An im-
munohistochemical study conducted on dogs has shown
that MMP-9, a factor of paramount importance for the
extracellular matrix homeostasis, is significantly decreasedFigure 6 Bisphosphonate effects on oral keratinocytes.in subjects treated with zoledronic acid, suggesting that
BPs promote epithelial cell apoptosis [45] (Figure 6). All
of the above mentioned abnormalities may in fact be at
work in BPs treated patients and they may act in concert
to promote extensive bone destruction as seen in BRONJ.
However, recent studies have revealed that the reduced
migration ability of various cell types of hard and soft
tissues such as bisphosphonate-treated human umbilical
cord vein endothelial cells (HUVEC), fibroblasts (nor-
mally a source of pro-angiogenic factors) and osteogenic
cells may be potentially prevented by administration of
factors with anti-BPs action. Some authors have claimed
that the mevalonate pathway metabolite, geranylgeraniol
(GGOH) or naturally occurring farnesol could an anti-
BPs effect healing the lesions seen in BRONJ [46,47].
Therefore, these factors may represent the basis for a po-
tential curative therapeutic protocol in BRONJ patients
but more validation studies are necessary before a pilot
study could be implemented [46,47].
Clearly bisphosphonates have a demonstrated multi-
modal ability to interfere with normal angiogenesis. Given
the critical role of vasculature development in tissues and
in particular bone, where the turnover rate is markedly
higher than in other tissues, this represents a potential
process that may therefore be intimately associated with
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that seen in the oral maxillofacial area of patients on
high potency bisphosphonates following routine dental
procedures.
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